Related Experiment Videos
Summary
Dextran enhances the breakdown of artificial blood clots (thrombi) in laboratory settings. This effect was observed both spontaneously and when using streptokinase, suggesting dextran may aid thrombolysis.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Artificial thrombi are used to study clot lysis.
- Dextran is a polysaccharide with potential effects on blood components.
- Streptokinase is a thrombolytic agent.
Purpose of the Study:
- To investigate the effect of dextran on the lysis of artificial thrombi.
- To determine optimal concentrations of dextran for enhanced thrombolysis.
- To compare dextran's effect with albumin and assess its applicability in human blood.
Main Methods:
- Artificial thrombi were formed using rabbit and human blood in a Chandler loop.
- Thrombolysis was assessed spontaneously and induced by varying concentrations of streptokinase.
- Dextran (Mw 40,000, 500,000, and dextran 70) and albumin were tested at different concentrations.
Main Results:
- Thrombi formed in the presence of dextran 70 showed greater spontaneous lysis than controls.
- Streptokinase-induced thrombolysis was maximized at specific dextran concentrations (2% for Mw 40,000/500,000, 1.2% for dextran 70).
- Albumin did not enhance thrombolysis, and similar results were observed with human blood.
Conclusions:
- Dextran significantly enhances both spontaneous and streptokinase-induced thrombolysis of artificial clots.
- Specific dextran concentrations are optimal for maximizing streptokinase-mediated clot breakdown.
- The findings suggest a potential role for dextran in augmenting thrombolytic therapies.